Cargando…

Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol

BACKGROUND: Momordica charantia Linnaeus (Cucurbitaceae) has been used traditionally as a nutritious food and as a herbal medicine for type 2 diabetes mellitus. However, human studies that investigated its glycemic control have generated inconsistent findings. Therefore, this systematic review and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Peter, Emanuel L., Deyno, Serawit, Mtewa, Andrew, Kasali, Félicien Mushagalusa, Nagendrappa, Prakash B., Sesaazi, Duncan, Tolo, Casim Umba, Ogwang, Patrick Engeu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238397/
https://www.ncbi.nlm.nih.gov/pubmed/30442186
http://dx.doi.org/10.1186/s13643-018-0847-x
_version_ 1783371370374103040
author Peter, Emanuel L.
Deyno, Serawit
Mtewa, Andrew
Kasali, Félicien Mushagalusa
Nagendrappa, Prakash B.
Sesaazi, Duncan
Tolo, Casim Umba
Ogwang, Patrick Engeu
author_facet Peter, Emanuel L.
Deyno, Serawit
Mtewa, Andrew
Kasali, Félicien Mushagalusa
Nagendrappa, Prakash B.
Sesaazi, Duncan
Tolo, Casim Umba
Ogwang, Patrick Engeu
author_sort Peter, Emanuel L.
collection PubMed
description BACKGROUND: Momordica charantia Linnaeus (Cucurbitaceae) has been used traditionally as a nutritious food and as a herbal medicine for type 2 diabetes mellitus. However, human studies that investigated its glycemic control have generated inconsistent findings. Therefore, this systematic review and meta-analysis is aimed at evaluating the safety and efficacy of M. charantia L. preparations in human studies that have investigated its role in glycemic control. METHODS: This protocol has been prepared according to Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). The review will include randomized clinical trials and non-randomized clinical trials. The included studies will have assessed glycemic control of M. charantia preparations with placebo or standard oral anti-hyperglycemic agents in adult pre-diabetes and/or type 2 diabetes mellitus patients and have at least 4 weeks of follow-up. The primary outcomes of review are fasting blood glucose levels, glycosylated hemoglobin A1c, and post-prandial blood glucose level. Electronic database search for published literatures will be conducted without language restriction in EMBASE, MEDLINE/PubMed, the Cochrane Library, SCOPUS, Web of Sciences, and CINAHL databases. Search for gray literatures and references of the retrieved full-text articles will be conducted in Google, Google Scholar, OpenGrey, ProQuest dissertations & Theses, British Library EThos, and university digital library systems. Two independent reviewers will later evaluate full texts, extract data, and assess risk of bias of eligible articles. Publication biases will be assessed by testing asymmetry of funnel plot using Egger’s or Begg’s tests while heterogeneity will be assessed using Cochran Q test, P value, and I(2). Revman software version 5.3 will be used for meta-analysis including subgroup and sensitivity analysis. DISCUSSION: This systematic review and meta-analysis will investigate both safety and efficacy of M. charantia preparations in type 2 diabetes mellitus. The review results will be published in a peer-reviewed journal. The results will bring better understanding of clinical outcomes in treatment of type 2 diabetes mellitus patients and highlight gaps for future research. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018083653. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13643-018-0847-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6238397
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62383972018-11-26 Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol Peter, Emanuel L. Deyno, Serawit Mtewa, Andrew Kasali, Félicien Mushagalusa Nagendrappa, Prakash B. Sesaazi, Duncan Tolo, Casim Umba Ogwang, Patrick Engeu Syst Rev Protocol BACKGROUND: Momordica charantia Linnaeus (Cucurbitaceae) has been used traditionally as a nutritious food and as a herbal medicine for type 2 diabetes mellitus. However, human studies that investigated its glycemic control have generated inconsistent findings. Therefore, this systematic review and meta-analysis is aimed at evaluating the safety and efficacy of M. charantia L. preparations in human studies that have investigated its role in glycemic control. METHODS: This protocol has been prepared according to Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). The review will include randomized clinical trials and non-randomized clinical trials. The included studies will have assessed glycemic control of M. charantia preparations with placebo or standard oral anti-hyperglycemic agents in adult pre-diabetes and/or type 2 diabetes mellitus patients and have at least 4 weeks of follow-up. The primary outcomes of review are fasting blood glucose levels, glycosylated hemoglobin A1c, and post-prandial blood glucose level. Electronic database search for published literatures will be conducted without language restriction in EMBASE, MEDLINE/PubMed, the Cochrane Library, SCOPUS, Web of Sciences, and CINAHL databases. Search for gray literatures and references of the retrieved full-text articles will be conducted in Google, Google Scholar, OpenGrey, ProQuest dissertations & Theses, British Library EThos, and university digital library systems. Two independent reviewers will later evaluate full texts, extract data, and assess risk of bias of eligible articles. Publication biases will be assessed by testing asymmetry of funnel plot using Egger’s or Begg’s tests while heterogeneity will be assessed using Cochran Q test, P value, and I(2). Revman software version 5.3 will be used for meta-analysis including subgroup and sensitivity analysis. DISCUSSION: This systematic review and meta-analysis will investigate both safety and efficacy of M. charantia preparations in type 2 diabetes mellitus. The review results will be published in a peer-reviewed journal. The results will bring better understanding of clinical outcomes in treatment of type 2 diabetes mellitus patients and highlight gaps for future research. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018083653. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13643-018-0847-x) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-15 /pmc/articles/PMC6238397/ /pubmed/30442186 http://dx.doi.org/10.1186/s13643-018-0847-x Text en © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Protocol
Peter, Emanuel L.
Deyno, Serawit
Mtewa, Andrew
Kasali, Félicien Mushagalusa
Nagendrappa, Prakash B.
Sesaazi, Duncan
Tolo, Casim Umba
Ogwang, Patrick Engeu
Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol
title Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol
title_full Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol
title_fullStr Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol
title_full_unstemmed Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol
title_short Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol
title_sort safety and efficacy of momordica charantia linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238397/
https://www.ncbi.nlm.nih.gov/pubmed/30442186
http://dx.doi.org/10.1186/s13643-018-0847-x
work_keys_str_mv AT peteremanuell safetyandefficacyofmomordicacharantialinnaeusinprediabetesandtype2diabetesmellituspatientsasystematicreviewandmetaanalysisprotocol
AT deynoserawit safetyandefficacyofmomordicacharantialinnaeusinprediabetesandtype2diabetesmellituspatientsasystematicreviewandmetaanalysisprotocol
AT mtewaandrew safetyandefficacyofmomordicacharantialinnaeusinprediabetesandtype2diabetesmellituspatientsasystematicreviewandmetaanalysisprotocol
AT kasalifelicienmushagalusa safetyandefficacyofmomordicacharantialinnaeusinprediabetesandtype2diabetesmellituspatientsasystematicreviewandmetaanalysisprotocol
AT nagendrappaprakashb safetyandefficacyofmomordicacharantialinnaeusinprediabetesandtype2diabetesmellituspatientsasystematicreviewandmetaanalysisprotocol
AT sesaaziduncan safetyandefficacyofmomordicacharantialinnaeusinprediabetesandtype2diabetesmellituspatientsasystematicreviewandmetaanalysisprotocol
AT tolocasimumba safetyandefficacyofmomordicacharantialinnaeusinprediabetesandtype2diabetesmellituspatientsasystematicreviewandmetaanalysisprotocol
AT ogwangpatrickengeu safetyandefficacyofmomordicacharantialinnaeusinprediabetesandtype2diabetesmellituspatientsasystematicreviewandmetaanalysisprotocol